FDG PET-CT在食管癌放化疗中的应用

doi:10.3760/cma.j.issn.1004-4221.2017.08.024

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (773 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Esophageal cancer is one of the most common gastrointestinal cancers, and chemoradiotherapy is an important part of the multidisciplinary treatment for this disease. In recent years, ¹⁸Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET-CT) is widely used in esophageal cancer for delineation of gross tumor volume, local boost irradiation in the late stage of radiotherapy, and assessment of the pathologic remission rate after neoadjuvant chemoradiotherapy, response to definitive chemoradiotherapy, and prognosis. In this article, we review the application of FDG PET-CT in the chemoradiotherapy for esophageal cancer.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Gu Feiying
	Jiang Chenxue
	Xu Yaping

Key words： Tomography,positron,emission Fluorine-deoxyglucose Esophageal neoplasms/chemoradiotherapy

Received: 10 August 2016

Corresponding Authors: :Xu Yaping,Email:xuyp@zjcc.org.cn

Cite this article:

Gu Feiying,Jiang Chenxue,Xu Yaping. Application of FDG PET-CT in chemoradiotherapy for esophageal cancer[J]. Chinese Journal of Radiation Oncology, 2017, 26(8): 961-964.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.issn.1004-4221.2017.08.024 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2017/V26/I8/961

[1] Chen WQ,Zheng RS,Baade PD,et al. Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.DOI:10.3322/caac.21338.
[2] Pennathur A,Gibson MK,Jobe BA,et al. Oesophageal carcinoma[J].Lancet,2013,381(9864):400-412.DOI:10.1016/s0140-6736(12)60643-6.
[3] 袁双虎,于金明,于甬华,等.¹⁸F-脱氧葡萄糖PET-CT检测食管癌病变长度的临床价值[J].中华放射肿瘤学杂志,2006,15(5):389-392.DOI:10.3760/j.issn:1004-4221.2006.05.009.
Yuan SH,Yu JM,Yu YH,et al. The clinical value of ¹⁸F-fluorodeoxyglucose PET-CT detection of lesion of esophageal carcinoma[J].Chin J Radiot Oncol,2006,15(5):389-392.
[4] Zhong XJ,Yu JM,Zhang BJ,et al. Using ¹⁸F-fluorodeoxyglucose positron emission tomography to estimate the length of gross tumor in patients with squamous cell carcinoma of the esophagus[J].Int J Radiat Oncol Biol Phys,2009,73(1):136-141.DOI:10.1016/j.ijrobp.2008.04.015.
[5] Han D,Yu JM,Yu YH,et al. Comparison of ¹⁸F-fluorothymidine and ¹⁸F-fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus[J].Int J Radiat Oncol Biol Phys,2010,76(4):1235-1241.DOI:10.1016/j.ijrobp.2009.07.1681.
[6] Yu W,Fu XL,Zhang YJ,et al. A prospective evaluation of staging and target volume definition of lymph nodes by ¹⁸FDG PET/CT in patients with squamous cell carcinoma of thoracic esophagus[J].Int J Radiat Oncol Biol Phys,2011,81(5):e759-e765.DOI:10.1016/j.ijrobp.2010.10.065.
[7] Karashima R,Watanabe M,Imamura Y,et al. Advantages of FDG-PET/CT over CT alone in the preoperative assessment of lymph node metastasis in patients with esophageal cancer[J].Surg Today,2015,45(4):471-477.DOI:10.1007/s00595-014-0965-6.
[8] Shi WD,Wang WC,Wang J,et al. Meta-analysis of ¹⁸FDG PET-CT for nodal staging in patients with esophageal cancer[J].Surg Oncol,2013,22(2):112-116.DOI:10.1016/j.suronc.2013.02.003.
[9] Wang GM,Liu DF,Xu YP,et al. PET/CT imaging in diagnosing lymph node metastasis of esophageal carcinoma and its comparison with pathological findings[J].Eur Rev Med Pharmacol Sci,2016,20(8):1495-1500.
[10] 郭延娈,李建彬,李奉祥,等.基于PET-CT的SUV值与基于4DCT的EE时相勾画胸段食管癌GTV相关性分析[J].中华放射肿瘤学杂志,2015,24(2):121-125.DOI:10.3760/cma.j.issn.1004-4221.2015.02.005.
Guo YL,Li JB,Li FX,et al. Correlation analysis between SUV value and 4DCT based EE delineation of thoracic esophageal carcinoma based on PET-CT and GTV[J].Chin J Radiat Oncol,2015,24(2):121-125.DOI:10.3760/cma.j.issn.1004-4221.2015.02.005.
[11] Muijs CT,Beukema JC,Pruim J,et al. A systematic review on the role of FDG-PET/CT in tumour delineation and radiotherapy planning in patients with esophageal cancer[J].Radiother Oncol,2010,97(2):165-171.DOI:10.1016/j.radonc.2010.04.024.
[12] Muijs CT,Beukema JC,Woutersen D,et al. Clinical validation of FDG-PET/CT in the radiation treatment planning for patients with oesophageal cancer[J].Radiother Oncol,2014,113(2):188-192.DOI:10.1016/j.radonc.2014.10.016.
[13] Welsh J,Settle SH,Amini A,et al. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation[J].Cancer,2012,118(10):2632-2640.DOI:10.1002/cncr.26586.
[14] Calais J,Dubray B,Nkhali L,et al. High FDG uptake areas on pre-radiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for locally advanced oesophageal cancer[J].Eur J Nucl Med Mol Imaging,2015,42(6):858-867.DOI:10.1007/s00259-015-3004-y.
[15] Yu W,Cai XW,Liu Q,et al. Safety of dose escalation by simultaneous integrated boosting radiation dose within the primary tumor guided by ¹⁸FDG-PET/CT for esophageal cancer[J].Radiother Oncol,2015,114(2):195-200.DOI:10.1016/j.radonc.2014.12.007.
[16] 刘琪,余雯,蔡旭伟,等.PET-CT用于评价食管鳞癌放疗中 ¹⁸F-FDG高摄取区域的空间动态变化的前瞻性研究[J].中国癌症杂志,2016,26(2):161-167.DOI:10.3969/j.issn.1007-3969.2016.02.008.
Liu Q,Yu W,Cai XW,et al. PET-CT was used to evaluate the spatial dynamic changes of ¹⁸FDG high uptake areas in radiotherapy for esophageal squamous cell carcinoma[J].Chin Oncol,2016,26(2):161-167.DOI:10.3969/j.issn.1007-3969.2016.02.008.
[17] Nkhali L,Thureau S,Edet-Sanson A,et al. FDG-PET/CT during concomitant chemo radiotherapy for esophageal cancer:reducing target volumes to deliver higher radiotherapy doses[J].Acta Oncol,2015,54(6):909-915.DOI:10.3109/0284186X.2014.973062.
[18] Van Heijl M,Omloo JM,Van Berge Henegouwen MI,et al. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer[J].Ann Surg,2011,253(1):56-63.DOI:10.1097/SLA.0b013e3181f66596.
[19] Huang JW,Yeh HL,Hsu CP,et al. To evaluate the treatment response of locally advanced esophageal cancer after preoperative chemoradiotherapy by FDG-PET/CT scan[J].J Chin Med Assoc,2015,78(4):229-234.DOI:10.1016/j.jcma.2014.11.003.
[20] Kukar M,Alnaji RM,Jabi F,et al. Role of repeat ¹⁸F-fluorodeoxyglucose positron emission tomography examination in predicting pathologic response following neoadjuvant chemoradiotherapy for esophageal adenocarcinoma[J].JAMA Surg,2015,150(6):555-562.DOI:10.1001/jamasurg.2014.3867.
[21] Tani Y,Nakajima M,Kikuchi M,et al.¹⁸F-fluorodeoxyglucose positron emission tomography for evaluating the response to neoadjuvant chemotherapy in advanced esophageal cancer[J].Anticancer Res,2016,36(1):367-373.
[22] Kim SJ,Koo PJ,Chang S.Predictive value of repeated F-18 FDG PET/CT parameters changes during preoperative chemoradiotherapy to predict pathologic response and overall survival in locally advanced esophageal adenocarcinoma patients[J].Cancer Chemother Pharmacol,2016,77(4):723-731.DOI:10.1007/s00280-016-2988-8.
[23] Piessen G,Petyt G,Duhamel A,et al. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer[J].Ann Surg,2013,258(1):66-76.DOI:10.1097/SLA.0b013e31828676c4.
[24] Stiekema J,Vermeulen D,Vegt E,et al. Detecting interval metastases and response assessment using ¹⁸F-FDG PET/CT after neoadjuvant chemoradiotherapy for esophageal cancer[J].Clin Nucl Med,2014,39(10):862-867.DOI:10.1097/RLU.0000000000000517.
[25] Elliott JA,O′Farrell NJ,King S,et al. Value of CT-PET after neoadjuvant chemoradiation in the prediction of histological tumour regression,nodal status and survival in oesophageal adenocarcinoma[J].Br J Surg,2014,101(13):1702-1711.DOI:10.1002/bjs.9670.
[26] Park JK,Kim JJ,Moon SW.A study about different findings of PET-CT between neoadjuvant and non-neoadjuvant therapy:SUV_max is not a reliable predictor of lymphatic involvement after neoadjuvant therapy for esophageal cancer[J].J Thorac Dis,2016,8(5):784-794.DOI:10.21037/jtd.2016.03.20.
[27] Liu Q,Fu XL,Yu W,et al. Potential values of metabolic tumor volume and heterogeneity measured with ¹⁸F-FDG PET/CT pretreatment to evaluate local control for esophageal squamous cell carcinoma treated with nonsurgical therapy[J].Nucl Med Commun,2015,36(5):423-429.DOI:10.1097/MNM.0000000000000267.
[28] Atsumi K,Nakamura K,Abe K,et al. Prediction of outcome with FDG-PET in definitive chemoradiotherapy for esophageal cancer[J].J Radiat Res,2013,54(5):890-898.DOI:10.1093/jrr/rrt021.
[29] Vatankulu B,Sanl Y,Kaytan SaglamE,et al. Does metastatic lymph node SUV_max predict survival in patients with esophageal cancer?[J].Mol Imaging Radionucl Ther,2015,24(3):120-127.DOI:10.4274/mirt.36744.
[30] 谢彦婷,郑容,吴宁,等.疗前FDG PET-CT代谢参数与食管癌放疗预后关系初步研究[J].中华放射肿瘤学杂志,2016,25(5):452-456.DOI:10.3760/cma.j.issn.1004-4221.2016.05.007.
Xie YT,Zheng R,Wu N,et al. Preliminary study of the relationship between metabolic parameters of FDG and PET-CT before radiotherapy and prognosis of radiotherapy for esophageal carcinoma[J].Chin J Radiat Oncol,2016,25(5):452-456.DOI:10.3760/cma.j.issn.1004-4221.2016.05.007.
[31] Cuenca X,Hennequin C,Hindié E,et al. Evaluation of early response to concomitant chemoradiotherapy by interim ¹⁸F-FDG PET/CT imaging in patients with locally advanced oesophageal carcinomas[J].Eur J Nucl Med Mol Imaging,2013,40(4):477-485.DOI:10.1007/s00259-012-2325-3.
[32] Vera P,Dubray B,Palie O,et al. Monitoring tumour response during chemo-radiotherapy:a parametric method using FDG-PET/CT images in patients with oesophageal cancer[J].EJNMMI Res,2014,4(1):12.DOI:10.1186/2191-219X-4-12.
[33] Seol KH,Lee JE.PET/CT planning during chemoradiotherapy for esophageal cancer[J].Radiat Oncol J,2014,32(1):31-42.DOI:10.3857/roj.2014.32.1.31.
[34] Li YM,Lin Q,Luo ZM,et al. Value of sequential ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) in prediction of the overall survival of esophageal cancer patients treated with chemoradiotherapy[J].Int J Clin Exp Med,2015,8(7):10947-10955.